Alteplase Dosing for Cardiac Arrest Due to Pulmonary Embolism
For a patient in cardiac arrest from massive PE, administer alteplase 50 mg as an immediate intravenous bolus. 1, 2, 3
Immediate Administration Protocol
Give 50 mg alteplase as a rapid IV bolus when cardiac arrest is imminent or already occurring due to confirmed or highly suspected massive PE. 1, 2, 3
This bolus can be administered over 2-15 minutes during active cardiopulmonary resuscitation. 2, 4
Continue CPR for at least 30 minutes after alteplase administration to allow time for the medication to work and achieve return of spontaneous circulation (ROSC). 2, 4
The 50 mg bolus dose is specifically recommended by the British Thoracic Society for patients in cardiac arrest or rapidly deteriorating, and is supported by the American Heart Association guidelines for PE-related cardiac arrest. 1, 2
Reassessment and Repeat Dosing
Reassess the patient 30 minutes after the initial bolus. 1
If ROSC is achieved but bedside echocardiography shows persistent severe right ventricular dysfunction with ongoing hemodynamic compromise, consider a second 50 mg bolus. 5
The mean cumulative alteplase dose in patients who achieved ROSC was significantly higher (90.6 mg) than in those who did not (69.4 mg), suggesting that additional dosing may be beneficial in select cases. 6
Critical Timing Considerations
Do not delay thrombolysis for imaging confirmation if the patient is in cardiac arrest or peri-arrest with high clinical suspicion of massive PE. 1, 2, 3
Bolus-only dosing strategies result in significantly shorter time from cardiac arrest onset to alteplase administration (mean 15.1 minutes) compared to infusion-based strategies (46-48 minutes). 6
Early administration of systemic thrombolysis is associated with improved resuscitation outcomes compared to use after failure of conventional advanced cardiac life support. 2
Contraindications in the Arrest Setting
In life-threatening massive PE with cardiac arrest, standard contraindications to thrombolysis may be superseded by the need for potentially lifesaving intervention, given the 52-65% mortality without treatment. 2, 3
Even absolute contraindications such as recent intracranial surgery may be overridden when the patient is in cardiac arrest from massive PE, as documented in successful case reports. 7
Post-ROSC Management
Resume unfractionated heparin 3 hours after completion of alteplase using weight-adjusted dosing to maintain therapeutic anticoagulation. 3, 8
Monitor closely for bleeding complications, which occur in 10-40% of patients receiving thrombolysis for PE, though fatal hemorrhage remains rare in the cardiac arrest setting. 3, 4
Alternative Dosing for Hemodynamically Stable Massive PE
If the patient has massive PE with sustained hypotension (systolic BP <90 mmHg) but is not yet in cardiac arrest, the standard dose is alteplase 100 mg as a continuous IV infusion over 2 hours via peripheral vein. 3, 8
This is the FDA-approved regimen for massive PE with hemodynamic instability. 3
Key Clinical Pitfalls
Do not use the 100 mg infusion protocol during active cardiac arrest—the 50 mg bolus is the appropriate dose in this setting. 1, 2
Do not stop CPR prematurely; thrombolysis requires time to work, and ROSC may not occur for 6-30 minutes after administration. 4
Do not withhold thrombolysis in suspected PE during cardiac arrest while waiting for confirmatory imaging—pulseless electrical activity with witnessed arrest and risk factors for PE is sufficient to proceed. 2